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Abstract
Metronomic chemotherapy using cyclophosphamide (CPA) is widely associated with antiangiogenesis; however,
recent studies implicate other immune-based mechanisms, including antitumor innate immunity, which can induce
major tumor regression in implanted brain tumor models. This study demonstrates the critical importance of drug
schedule: CPA induced a potent antitumor innate immune response and tumor regression when administered inter-
mittently on a 6-day repeating metronomic schedule but not with the same total exposure to activated CPA admin-
istered on an every 3-day schedule or using a daily oral regimen that serves as the basis for many clinical trials of
metronomic chemotherapy. Notably, the more frequent metronomic CPA schedules abrogated the antitumor innate
immune and therapeutic responses. Further, the innate immune response and antitumor activity both displayed an
unusually steep dose-response curve and were not accompanied by antiangiogenesis. The strong recruitment of
innate immune cells by the 6-day repeating CPA schedule was not sustained, and tumor regression was abolished,
by a moderate (25%) reduction in CPA dose. Moreover, an ∼20% increase in CPA dose eliminated the partial tumor
regression and weak innate immune cell recruitment seen in a subset of the every 6-day treated tumors. Thus,
metronomic drug treatment must be at a sufficiently high dose but also sufficiently well spaced in time to induce
strong sustained antitumor immune cell recruitment. Many current clinical metronomic chemotherapeutic protocols
employ oral daily low-dose schedules that do not meet these requirements, suggesting that they may benefit from
optimization designed to maximize antitumor immune responses.
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Introduction
Metronomic chemotherapy involves the administration of cancer
chemotherapeutic drugs at regular intervals, without long breaks,
and is thought to yield improved antitumor activity through anti-
angiogenesis combined with conventional drug cytotoxicity [1–4].
Metronomic schedules investigated in preclinical studies include
intermittent drug dosing, e.g., the 6-day repeating metronomic
schedule empirically found to be most efficacious by Browder et al.
[1], as well as daily oral low-dose treatment regimens, which are pro-
posed to be even more effective in killing tumor endothelial cells [5,6].
Metronomic drug schedules have been evaluated in clinical trials,
primarily using daily dosing regimens, with promising results [7–9].
Recent studies have shown that other mechanisms, notably antitumor
immunity, may also be activated by metronomic chemotherapy. For
example, metronomic administration of gemcitabine and docetaxel
restores lymphocyte effector function by suppressing bone marrow–
derived suppressor cells [10,11], while paclitaxel, cyclophosphamide
(CPA), temozolomide and vinorelbine preferentially deplete regulatory
T suppressor cells (Tregs) [12–15]. Furthermore, CPA administration
Abbreviations: CPA, cyclophosphamide; MTD, maximum tolerated dose; NK, natural
killer; Prf1, perforin-1
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on an every 6-day metronomic schedule stimulates antitumor innate
immune cell recruitment, which is associated with marked regression of
implanted brain tumors in both severe combined immunodeficiency
(SCID) immune-deficient and immune-competent mice [16]. Tumor
regression is incomplete when natural killer (NK) cells are immuno-
depleted from fully immune-competent mice bearing subcutaneous
syngeneic GL261 gliomas, demonstrating the importance of the innate
immune system in tumor regression induced by CPA given on an every
6-day metronomic schedule [16].
Metronomic chemotherapy has shown therapeutic benefits be-
yond those observed with conventional maximum tolerated dose
chemotherapy and can induce responses in patients where standard
chemotherapy is no longer effective [7,8]. For example, daily metro-
nomic vinorelbine treatment increases progression-free survival and
overall survival in elderly patients with metastatic breast cancer
[17]. Intermittent metronomic administration of vinorelbine and
cisplatin using optimized doses and schedules gives favorable clinical
responses in patients with advanced/metastatic non–small cell lung
carcinoma [18], and prolonged responses are achieved in patients
with refractory cancers given vinorelbine on a thrice weekly metro-
nomic schedule [13]. A striking 65-month progression-free survival
was reported in a patient with stage IIIC ovarian cancer given metro-
nomic CPA on a daily schedule without side effects [19], and metro-
nomic irinotecan administration in patients with metastatic colorectal
cancer resulted in stable disease despite progression following initial
treatment with a standard irinotecan regimen [20]. Furthermore,
metronomic regimens generally show reduced toxicity compared to
maximum tolerated dose (MTD) regimens, and by avoiding the
dose-dense exposure of MTD schedules, metronomic administration
of CPA, as well as other agents, avoids immunosuppression and in-
stead allows for antitumor immune activation [21]. While it is often
assumed that the antiangiogenic activity of metronomic chemotherapy
contributes to these therapeutic responses, other mechanisms, includ-
ing antitumor immune responses, may also be at work. Little is known,
however, about the requirements, in terms of schedule and dose, to
induce metronomic chemotherapy-activated antitumor immunity, a
prerequisite for translating preclinical studies of immune-activating
metronomic chemotherapeutic regimens to the clinic.
Here, we investigated a recently described brain tumor xenograft
model of metronomic CPA-induced antitumor innate immunity
[16] to determine the schedule and dose requirements for innate
immune cell recruitment and activation leading to tumor regression.
We found that tumor recruitment and activation of innate immune
cells, including macrophages, dendritic cells, and NK cells, by an
intermittent 6-day repeating schedule of metronomic CPA is severely
compromised when using dose-equivalent but more frequent metro-
nomic CPA schedules, most notably the daily oral CPA regimen that
has served as a model for many clinical trials of metronomic chemo-
therapy. Furthermore, we report an unexpectedly steep dose-response
curve for activation of antitumor innate immunity by the every
6-day metronomic schedule, with a strong correlation seen between
innate immune cell recruitment and individual tumor regression
responses. Together, our findings support the conclusion that to
achieve an effective antitumor immune response, metronomic CPA
must be at a dose that is sufficiently high to induce tumor or stromal
cell damage leading to the activation of antitumor innate immunity
but also sufficiently well spaced in time to not ablate responding anti-
tumor immune cells, some of which may be particularly sensitive to
drug cytotoxicity.
Materials and Methods
Cell Lines and Reagents
CPA monohydrate was purchased from Sigma Chemical Co (St
Louis, MO). FBS and Dulbecco’s modified Eagle’s medium (DMEM)
culture medium were purchased from Invitrogen (Frederick, MD). The
rat 9L gliosarcoma cell line was authenticated by and obtained from the
Neurosurgery Tissue Bank at University of California, San Francisco
(UCSF; San Francisco, CA) and grown at 37°C in a humidified,
5% CO2 atmosphere in 10% FBS, 100 units/ml penicillin, and
100 μg/ml streptomycin containing DMEM culture medium.
Quantitative Polymerase Chain Reaction Analysis
Methods for isolation of total RNA from frozen tumor tissue,
reverse transcription, and quantitative polymerase chain reaction
(qPCR) analysis (primers shown in Table W1 and in [16]) are de-
scribed [16]. Primers designed using Primer Express software (Applied
Biosystems, Carlsbad, CA) were evaluated using LaserGene software
(DNAStar, Madison, WI) to ensure mouse gene specificity, except
as noted. The absence of cross-species amplification was verified
by testing each primer pair on a panel comprising rat liver, human
umbilical vein endothelial cells (HUVEC), and mouse liver RNA, in
addition to rat 9L and human U251 tumor cell RNA. Data were
analyzed using the comparative CT (ΔΔCT) method and are presented
as relative levels of each RNA compared to the RNA level in untreated
tumors after normalization to the 18S RNA content of each sample.
Tumor Xenograft Studies
Five- to 6-week-old (24-26 g) male ICR/Fox Chase immune-
deficient SCID mice (Taconic Farms, Germantown, NY) were housed
in the Boston University Laboratory of Animal Care Facility and
treated in accordance with approved protocols and federal guidelines.
9L cells (4 × 106 cells) were injected subcutaneous (s.c.) on each pos-
terior flank in 0.2 ml of serum-free DMEM using a 0.5-inch 29-gauge
needle and a 0.3-ml insulin syringe. Tumor areas (length × width)
were measured twice weekly using Vernier calipers (VWR, Cat. No.
62379-531), and tumor volumes were calculated on the basis of vol =
(π/6) * (L * W )3/2. Tumors were monitored, and treatment groups
were normalized (each tumor volume was set to 100%) once average
tumor volumes reached ∼300 mm3. Mice were treated with CPA given
on the following metronomic schedules: oral dosing [23.3 or 70 mg/kg
body weight (BW) per day] [6] or intermittent bolus dosing by intra-
peritoneal (i.p.) injection (70 mg/kg BW, i.p., every 3 days or 70, 105,
140, or 170 mg/kg BW, i.p., every 6 days) on days indicated in each
figure by vertical arrows along the X-axis. CPA was given orally through
drinking water [5] using 0.7 or 2.1 mg of CPA per 4.5 ml of sterile tap
water based on a measured water consumption rate of 0.15 ml/g mouse
BW per day. All doses are based on the weight of CPA monohydrate.
Tumor sizes and mouse body weights were measured at least twice a
week. Tumor growth rates before drug treatment were similar among
all normalized groups. The plasma pharmacokinetics of 4-OH–CPA
exposure was assayed in 9L tumor-bearing mice given CPA by i.p.
injection at 70 or 140 mg/kg BW (n = 4 mice per group). We were
unable to obtain consistent 4-OH–CPA plasma pharmacokinetic
data for the 23.3 mg/kg BW/day oral dosing (drinking water) group
[1x per oral (p.o.) dosing], presumably because of the variable time
and volume of the last ad lib exposure to CPA. To estimate the phar-
macokinetics of ad lib drinking water exposure to CPA, we assumed
that the mice drink five times per day on average. Accordingly, CPA
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was administered by oral gavage at 11.65 mg/kg BW (n = 4 mice),
corresponding to 20% of the daily doses of 58.25 mg/kg BW
(2.5× p.o. dosing). Blood samples were obtained at t = 0 (before CPA
exposure) and at t = 5 to t = 240 minutes after CPA dosing by retro-
orbital bleeding (100 μl/mouse per time point × four mice), for both
the i.p. and the p.o. exposure routes. 4-OH–CPA levels were assayed,
and pharmacokinetic parameters were calculated usingWinNonlin soft-
ware [22]. Area under the curve (AUC) values, in units of (nmol/ml) ×
hour, were normalized to take into account the frequency of adminis-
tration of each regimen. Thus, “daily AUC” values (Figure 1C ) were
obtained by multiplying the measured AUC values for the 2.5× p.o.
group by 5 (cf., 20% of a daily dose given by gavage) and by dividing
themeasured AUCvalues of the 70mg/kg per 3-day i.p. and 140mg/kg
per 6-day i.p. groups by 3 and 6, respectively. The daily AUC of 9.8
(hour × nmol/ml) for 4-OH–CPA exposure measured here in SCID
mice given 1× p.o. CPA dosing is very similar to the daily AUC value
of 10.3 (hour × nmol/ml) for the same dosing regimen and route (20mg
CPA/kg per day, p.o.) reported by others in C57BL/6J mice [6] (the
56-day AUC value shown in Table 1 of that study was divided by 56
to obtain the daily AUC value).
Tissue Processing and Immunohistochemistry
Tumors were collected on day 6 after the second, third, and fourth
cycles of metronomic CPA based on the 6-day repeating schedule,
Figure 1. Impact of metronomic schedule on CPA-induced antitumor innate immunity and tumor regression. (A) Growth of 9L xenografts
in SCID mice, either untreated (UT) or given metronomic CPA treatment daily, through drinking water at 23.3 mg/kg BW (1× p.o.) or
70 mg/kg BW (3× po) or by i.p. injection every 3 days at 70 mg/kg BW or every 6 days at 140 mg/kg BW. X-axis, treatment day. Data are
themean±SE tumor volumes forn=5 to6mice per treatment group. *P< .05, **P< .01, and ***P< .001 compared toUTonday 24; &&P<
.01 and &&&P < .001 compared to 3× p.o. schedule on day 30; and #P < .05 compared to 70 i.p. schedule on day 30, by one-way ANOVA
with Bonferroni multiple comparison correction. (B) Pharmacokinetics of 4-OH–CPA (active metabolite of CPA) levels in plasma of tumor-
bearing SCID mice following metronomic CPA treatment using the schedules indicated. (C) Daily AUC for plasma 4-OH–CPA exposure in
SCID mice treated with the indicated metronomic CPA regimens, based on mean ± SE values for n = 4 mice per time point, based on the
data in B and normalized to adjust for the frequency of administration of each regimen, as described in Materials and Methods section.
(D) qPCR analysis of host (mouse) macrophagemarker CD68, dendritic cell marker CD74, and NK cell marker NKp46 in 9L tumor xenografts,
untreated or treated with the indicated metronomic CPA regimens. Tumors were excised on day 0, and on treatment days 12, 18, and
24 (based on A), corresponding to 6 days after two, three, and four cycles of 6-day repeating CPA treatment, as marked along X-axis. Bars,
mean ± SE for each treatment group and time point. *P < .05, **P < .01, and ***P < .001, for each CPA treatment schedule and time
point (n = 2-5 mice per group) versus UT controls (n = 10 mice). Data were analyzed by one-way ANOVA with Bonferroni multiple com-
parison correction for one tumor randomly selected from each mouse.
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i.e., on days 12, 18, and 24 after the first CPA treatment or as indicated
in each figure. Tumors were excised and portions were frozen in liquid
nitrogen (for RNA, tissue cryosectioning, and immunohistochemistry).
A second portion was fixed in 4% paraformaldehyde overnight and
then dehydrated in 70% ethanol and embedded in paraffin at the
Maine Medical Center Research Institute (Scarborough, ME). Paraffin
sections (6 μm) were stained with hematoxylin, proliferating cell
nuclear antigen (PCNA), and CD31 after dewaxing with a tissue
deparaffinization solution (EZ-DeWax; BioGenex, Fremont, CA).
Cryosections to be stained with antibody to CD68, CD31, NK1.1,
or perforin-1 (Prf1) were fixed in acetone (NK1.1, Prf1) or 1% para-
formaldehyde (CD68, CD31). For both paraffin and frozen sections,
endogenous peroxidase was blocked for 5 minutes using 3% hydrogen
peroxide and protein blocking was performed for 20 minutes using 2%
or 5% normal animal serum from the species where the secondary
antibody was raised. Slides were incubated with primary antibody for
1 hour at room temperature (for PCNA and CD31 staining) or over-
night at 4°C (for CD68, NK1.1, and Prf1 staining). The following
antibodies were used: PCNA (PC10; Cell Signaling Technology,
Danvers, MA), anti-mouse CD31 (PECAM-1 antibody, 1:40 dilu-
tion for paraffin sections, Cat. No. DIA-310; Dianova, Hamburg,
Germany; anti-CD31 antibody, 1:1000 for cryosections, Cat. No.
557355; Pharmingen, San Diego, CA), goat anti-mouse NK1.1 (1:25,
CD161, clone M-15, Cat. No. sc-70150; Santa Cruz Biotechnology,
Santa Cruz, CA), rat anti-mouse CD68 (MCA1957, 1:100; AbD
seroTec, Raleigh, NC), and rat anti-mouse Prf1 (CB5.4, 1:250, Cat.
No. sc-58643; Santa Cruz Biotechnology). The following biotinylated
secondary antibodies were incubated for 45 to 60 minutes at room
temperature at a dilution of 1:200 to 1:250: horse anti-mouse (Cat.
No. BA-2000) for PCNA, rabbit anti-goat (Cat. No. BA-5000) for
NK1.1, and rabbit anti-rat (Cat. No. BA-4000) for CD31, CD68, and
Prf1. An avidin-biotin blocking kit (Cat. No. SP-2001; Vector Labora-
tories, Burlingame, CA) was used for all incubations, followed by ABC
signal amplification with Vector Laboratories Vectastain ABC peroxidase
reagent (ABC Elite Kit, Cat. No. PK-6100 or Cat. No. PK-4000). Slides
were then submerged in a substrate solution (VIP, Cat. No. SK-4600;
ImmPACT VIP, Cat. No. SK-4605; or DAB, Cat. No. SK-4105, all
from Vector Laboratories) for 5 to 10 minutes. Hematoxylin solution,
Harris Modified (Sigma; Cat. No. HHS128) for 5 minutes, followed
by washing with 5% acetic acid for 1 minute and Scott’s Tap Water
(Sigma; Cat. No. S5134) for 2 minutes, twice, was applied using a
BioGenex i6000 Autostainer. Stained tumor sections were visualized
under an Olympus BX51 microscope. Tiled images typically covering
4 to 15 nonoverlapping fields were collected (depending on tumor size)
and analyzed for at least three randomly selected regions (i.e., ∼10-
40 images) for each tumor. Images were captured with an Olympus
DP25 digital camera using Olympus DP2-BSW software. For stain
quantification, images were converted into 8-bit image files, a back-
ground threshold was determined using ImageJ software, and all images
were processed using an ImageJ software macro to quantify the area
of positive stain.
Tumor Excision and Cell Line Preparation
9L tumors were excised from individual mice under sterile condi-
tions in a laminar flow hood and cut to fine pieces (2-4 mm). Fine
tumor tissue (100-200 mg) was placed in a gentleMACS tube C con-
taining 8 ml of ice-cold DMEM containing 10% FBS, collagenase
type I (450 U/ml; Worthington Biochemical Corp, Lakewood, NJ),
and DNase I (0.1 mg/ml, D5025; Sigma) and minced in gentleMACS
Dissociator (MACS Miltenyl Biotec, Auburn, CA) using the manu-
facturer’s program “Run m_impTumor_02.” The tube was inverted
several times and incubated in a 37°C water bath for 20 minutes with
shaking. An additional 4500 U of collagenase and 1 mg of DNase I were
added, followed by a 20-minute incubation in a shaking 37°C water
bath. The sample was reprocessed in a gentleMACS Dissociator using
the program “Run m_impTumor_03,” centrifuged at 1000 rpm, and
filtered through a 70-μm filter into a 50-ml falcon tube. Cells were
washed with 10 ml of DMEM and centrifuged twice at 1000 rpm. Cells
were resuspended in 1 to 2ml ofDMEMcontaining 10%FBS, counted,
and plated onto two to three plates at different cell concentrations.
Colonies comprising ∼20 to 200 cells each were counted 9 to 14 days
later and collected as passage 0 and then frozen in liquid nitrogen.
Statistical Analysis
Data were analyzed for statistical significance by one-way analysis of
variance (ANOVA) with Bonferroni multiple comparison correction,
unless indicated otherwise, as implemented in GraphPad Prism 4.1.
Fisher exact test was additionally used to compare immune responses
in tumors showing complete regression to tumors showing partial re-
gression. Data analysis was carried out using one of the two tumors
implanted bilaterally in each mouse unless indicated otherwise. Tumors
included in the data presentation and statistical analysis were selected
at random (e.g., tumors excised from the right flank of each mouse).
Thus, the tumor growth rate data and immune factor expression are
based on n tumors in n mice per treatment group, as specified in each
figure legend.
Results
Optimized Intermittent Metronomic Timing Is Essential for
Antitumor Immune Activation and Tumor Regression
Metronomic CPA treatment of 9L and several other implanted brain
tumor models using an intermittent metronomic schedule (140 mg/kg,
i.p., repeated every 6 days) elicits potent antitumor immunity associated
with near-complete tumor regression. This regression is achieved in
both immunocompetent C57BL/6 mice and in T and B cell–deficient
SCID mice [16]. Because innate immune cell activation and the asso-
ciated tumor regression responses are fully preserved in the adaptive
immune cell–deficient SCID mice, which retain the entire suite of
innate immune cells, we used this model to further investigate the im-
pact of the metronomic schedule on innate immune cell–based tumor
regression. While daily (continuous) low-dose metronomic schedules
also show antitumor activity and have most often been used in the clinic
in the form of a daily orally administered chemotherapy regimen [7],
direct comparisons to the 6-day repeating bolus dose metronomic
CPA regimen have not been reported. Daily (oral) administration of
CPA at 23.3 mg/kg per day to SCID mice bearing 9L gliosarcoma
xenografts did not induce significant tumor growth delay. In con-
trast, near-complete tumor regression was induced when the same total
CPA dose over a 6-day period was given once every 6 days (140 mg/kg,
i.p., every 6 days; Figure 1A). Pharmacokinetic analysis of plasma drug
levels showed, however, that the oral CPA route resulted in underdosing
when compared to the every 6-day i.p. regimen and that a 2.5- to 3-fold
increase in the nominal oral dose was required to achieve equivalent
exposure to the i.p. CPA regimen, as determined by AUC values for
exposure to 4-OH–CPA (the active metabolite of CPA; Figure 1B) after
normalization based on the average total daily drug dose (see Materials
Neoplasia Vol. 16, No. 1, 2014 Metronomic Dose and Schedule Optimization Chen et al. 87
and Methods section; Figure 1C ). Consequently, we increased the
orally administered CPA dose three-fold, to 70 mg/kg per day, to allow
for comparison of the daily oral and the every 6-day i.p. schedules at
equivalent drug exposures. Nevertheless, only modest tumor growth
delay was achieved using the three-fold increased oral CPA dose (Fig-
ure 1A; 3× p.o. vs untreated). Furthermore, only a short period of tumor
growth stasis was obtained using an alternative intermittent schedule
(70 mg/kg, i.p., every 3 days), followed by tumor regrowth (Figure 1A).
Thus, the three metronomic CPA treatment schedules give an unexpect-
edly wide range of antitumor responses, despite their equivalence with
respect to net exposure to active drug.
Analysis of tumor tissue showed that the daily CPA regimen failed
to induce tumor recruitment of macrophages, dendritic cells, or NK
cells, as revealed by qPCR analysis of their respective markers (CD68,
CD74, and NKp46; 1× p.o. and 3× p.o.; Figure 1D). The 70 mg/kg
every 3-day regimen showed increased recruitment of macrophages but
not dendritic cells or NK cells, whereas the 140 mg/kg every 6-day
schedule activated broad-spectrum antitumor innate immunity, char-
acterized by significant recruitment of all three classes of immune cells
(Figure 1D). These findings were verified by immunohistochemical
analysis of infiltrating immune cell populations in cryosections pre-
pared from tumors excised on treatment day 24 (Figures 2A and
W1). Recruitment of macrophages (CD68 staining) was evident in
the every 3-day and every 6-day CPA-treated tumors, while NK cells
(NK1.1 and perforin staining) were evident in the every 6-day treated tu-
mors only. Quantitation of these results showed that only the 140 mg/kg
every 6-day schedule significantly increased tumor-associated macro-
phages and NK cells (Figure 2B). Overall, the antitumor response of
each metronomic CPA schedule correlated with the extent of recruit-
ment of one or more of immune cell classes (Figure 1A vs Figure 1D).
Thus, the activation of innate immune cell recruitment by metronomic
CPA that we reported previously [16] requires CPA administration on
an intermittent metronomic schedule, with sufficient time (i.e., 6 days)
between cycles of drug administration.
Figure 2. Metronomic CPA regimens have differential effects on antitumor innate immunity: (A) 9L tumor cryosections immunostained
for macrophage marker CD68 (×4.2), NK cell marker NK1.1 (×40), and NK cell effector perforin (Prf1; ×20). Tumor paraffin sections were
stained with hematoxylin for cell density, PCNA (cell proliferation), and endothelial cell marker CD31 (all at ×20). Tumors (excised day 24):
untreated or CPA treated [140 mg/kg BW, every 6 days and through drinking water (3× p.o.); as in Figure 1]. Representative photos based
on three to four independent tumor sections from each of n= 3 tumors randomly selected from n= 3mice per group for CD68, NK1.1, and
Prf1 and n = 2 to 5 mice per group for the histochemical stainings are shown. See also Figure W1. (B) ImageJ quantification of immuno-
stained macrophage marker CD68, NK cell markers NK1.1 and Prf1, and endothelial cell marker CD31, hematoxylin staining, and PCNA
staining normalized by relative cell density (i.e., hematoxylin staining) in untreated (UT) 9L tumors and in metronomic CPA-treated tumors
using the schedules indicated; tumors were analyzed on CPA treatment day 24. Error bars, mean ± SE for n = 3 to 6 tumors per group,
based on data averaged over 10 to 40 images analyzed per tumor. *P < .05, **P < .01, ***P < .001 compared to UT or CPA treatment,
as indicated, analyzed by one-way ANOVA with Bonferroni multiple comparison correction.
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Differential Effects of Metronomic Schedules on Tumor
Microenvironment and Innate Immune Cell Recruitment
To better understand the differential antitumor effects of each
metronomic CPA schedule, we investigated the expression of factors
that may be important for the observed antitumor responses. First,
we assayed the ability of each drug schedule to induce tumor cell
damage leading to initiation of a stress-mediated antitumor immune
response, as judged by tumor (rat) cell–specific expression of the in-
flammatory chemokines CXCL10 and CXCL11, which are activated
in response to damage associated with cytotoxic tumor cell stress [23]
and can promote chemotaxis of activated NK cells [24]. Tumor cell
expression of CXCL10 was significantly increased by both the every
3-day and the every 6-day CPA treatments, with similar increases
(albeit not statistically significant) seen with the daily CPA regimen.
Similar patterns were seen for CXCL11 (Figure 3A). Accordingly,
the ability of CPA to stimulate cytotoxic tumor cell stress, as mea-
sured by these markers, does not account for the CPA schedule
dependence of immune cell recruitment and antitumor responses.
Next, we investigated whether the three metronomic schedules have
differential cytotoxic effects on splenic immune cell reservoirs. Mac-
rophage levels were not affected by any of the metronomic regimens
(Figure 3B), suggesting that splenic macrophages are insensitive to
CPA, in agreement with our earlier finding with the every 6-day metro-
nomic schedule [16]. However, splenic levels of dendritic cell and NK
markers were generally decreased by all three CPA treatment regimens
(Figure W2). Interestingly, the neutrophil marker Gr1 showed the
greatest decreases with the every 3-day metronomic schedule, indicating
a schedule-dependent sensitivity to CPA (Figure W2).
The dependence of the NK cell response on the schedule of metro-
nomic CPA treatment was confirmed by analyzing the NK cell marker
NK1.1 and the NK cell receptor NKG2D, as well as the NK cell ef-
fectors perforin (Prf1) and granzyme B (GzmB), which consistently
showed the greatest responses to the every 6-day metronomic CPA
schedule (≥60-fold increases after four cycles; Figure 3C). Moreover,
in contrast to the responses to the tumor cell damage/stress response
chemokines CXCL10 and CXCL11, which were already maximal after
the second cycle of metronomic CPA (i.e., day 12 after the first CPA
treatment), the NK cell markers and cytotoxic effectors showed progres-
sive increases with each additional every 6-day CPA injection. The
host cell–expressed chemokine CXCL14, which is a chemoattractant
Figure 3. Metronomic CPA regimens have differential effects on chemokines, cytotoxic effectors, and immune markers. (A) Tumor cell
expression of chemokines CXCL10 and CXCL11 in 9L tumor xenografts treated as in Figure 1 and analyzed using rat (r)–specific qPCR
primers on pooled tumor RNA samples collected on treatment days 12, 18, and 24 (6 days after two, three, and four cycles of 6-day repeating
CPA treatment, as marked). (B) Expression of CD68 (macrophage marker) in spleens of tumor-bearing mice assayed in A. (C) Expression of
additional mouse immune markers in tumors analyzed as in A: NK cell marker NK1.1, NK cell effectors perforin (Prf1) and GzmB, activating
receptor NKG2D, CXCL14, and Fas ligand (FasL). Error bars, mean ± SD for n = 3 replicate assays of samples collected from tumors or
spleens from n= 2 to 4mice per treatment group. *P< .05, **P< .01, and ***P< .001 for comparisons of each CPA schedule after two to
four treatment cycles (days 12-24; A) or after three to four treatment cycles (days 18-24; C), compared to UT tumor controls, by one-way
ANOVA with Bonferroni multiple comparison correction. In A, both the 70/3-day and the 140/6-day CPA schedules were significantly differ-
ent from untreated controls, whereas in C, only the 140/6-day schedule showed significant differences, as marked.
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for macrophages, immature dendritic cells, and NK cells [25], was
significantly induced by the 6-day metronomic schedule only (Fig-
ure 3C). Finally, Fas ligand, which potentiates cell death by activating
Fas receptor, showed a pattern of response similar to that of perforin
and GzmB, namely, only the 6-day metronomic regimen showed sig-
nificant activation. Fas ligand increases macrophage cytotoxicity [26] as
well as NK cell contact-mediated cell death [27]. In vitro analyses con-
firmed that cultured 9L tumor cells are intrinsically sensitive to NK cell
cytotoxicity, as shown using NK92 cells activated with interleukin 2
(Marie Jordan, unpublished experiments).
Next, we investigated whether the three metronomic schedules in-
duced other differential effects within the tumor. Tumor cell density,
assayed by hematoxylin staining 24 days after the first CPA treat-
ment, was significantly decreased by both the 3-day and the 6-day
metronomic CPA schedules but not by the continuous daily regi-
mens (Figures 2, A and B, and W1B). Unexpectedly, significant in-
creases, rather than decreases, in cell proliferation were seen with the
6-day metronomic CPA schedule, as indicated by PCNA immuno-
staining normalized to the hematoxylin-staining intensity (Figure 2B).
Intense PCNA staining was seen in both the every 3-day and every
6-day CPA-treated tumors, but overall, staining was restricted to a
much smaller fraction of the tumor section area than in the daily
CPA-treated tumors and the untreated tumor controls (Figures 2A
and W1B). This increase in PCNA staining, as well as the change
in cell morphology apparent in the hematoxylin and PCNA-stained
tissue sections, may be indicative of the tumor-infiltrating immune
cells [28,29]. Finally, none of the metronomic CPA regimens caused
a significant decrease in tumor microvessel density, as evidenced by
CD31 staining (Figures 2 and W1B), indicating that metronomic che-
motherapy does not act through an antiangiogenic mechanism in the
case of these established and well-vascularized tumors. Therefore, the
observed regression of the 6-day metronomic CPA-treated tumors,
and the loss of tumor cellularity, cannot be explained by metronomic
chemotherapy-induced antiangiogenesis.
Metronomic CPA Dose Optimization for Sustained Antitumor
Innate Immune Cell Recruitment
Next, we investigated the dose dependence of the antitumor re-
sponses to the 6-day metronomic CPA treatment schedule (Figure 4A).
Antitumor activity was characterized by an unusually steep dose de-
pendence, with modest tumor growth delay seen at every 6-day doses
of 70 mg CPA/kg, initial tumor stasis followed by tumor regrowth at
105 mg CPA/kg, and major tumor regression after a delay of about
two to three treatment cycles at 140 and 170 mg CPA/kg. Investigation
of infiltrating immune cell markers revealed no significant immune
cell recruitment at 70 mg/kg CPA. Several immune markers were sig-
nificantly increased after four cycles of metronomic CPA (treatment
day 24) at the 105 mg/kg dose, at which time the tumors were nearly
growth static; however, these immune responses declined with further
cycles of CPA treatment (Figure 4B, seven CPA cycles) in association
with the resumption of tumor growth (Figure 4A). In contrast, the
innate immune cell responses were sustained through seven CPA cycles
at both the 140 and 170 mg/kg doses (Figure 4B) in association with
the observed patterns of marked tumor regression (Figure 4A). These
Figure 4. Impact of dose of metronomic/6-day CPA schedule on tumor response and innate immune recruitment. (A) Tumor volumes for
9L xenografts, either untreated (UT) or given metronomic CPA treatment every 6 days (black arrows) at 70, 105, 140, or 170 mg CPA/kg BW
per i.p. injection. Error bars, mean ± SE for n = 10 to 12 mice per treatment group. (B, C) Expression of the indicated immune cell and
chemokinemarkers in tumors assayed on day 6 after either four or seven CPA cycles, corresponding to treatment days 24 and 42 in A. Error
bars, mean ± SE for n = 2 to 4 mice per treatment group. *, **, ***P < .05, .01, and .001, respectively, versus UT (CPA dose of 0 mg/kg
BW). ^, ^^P< .05 and .01, respectively, versus CPA dose of 105 mg/kg BW treatment on day 6 after seven cycles of CPA treatment. Data
were analyzed by one-way ANOVA with Bonferroni multiple comparison correction for one tumor randomly selected from each mouse
(B and C). See also Figure W3.
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findings were verified using a more complete panel of NK cell markers
as well as Fas ligand (Figure W3).
Significant increases in tumor cell expression of CXCL10 were seen
at metronomic CPA doses of 105, 140, and 170 mg/kg. Maximum
increases in CXCL10 occurred at the 105 mg/kg dose (Figure 4C ),
perhaps reflecting the decreases in tumor cell density at the higher
CPA doses (Figure W4). This finding is consistent with our conclu-
sion, based on Figure 3A, that CXCL10 induction marks tumor cell
exposure to activated CPA but is not predictive of immune cell recruit-
ment or antitumor response. Furthermore, significant and sustained
increases in the NK cell–recruiting host (mouse) chemokine CXCL14
were seen at the metronomic CPA doses of 140 and 170 mg/kg, with
the 105 mg/kg dose inducing an initial but transient elevation of
CXCL14 (Figure W3).
Robust Innate Immune Recruitment Is Required for
Complete Tumor Regression
During the course of these studies, we noted several individual 9L
tumors that initially regressed when treated with CPA at 140 mg/kg
on the every 6-day schedule but that did not regress further
(i.e., tumors became growth static), despite ongoing metronomic
CPA treatment (Figure 5A, partially regressing tumors vs Figure 5B,
fully regressing tumors). Other individual tumors exhibited growth de-
lay without regression (Figure 5A), similar to tumors treated with CPA
Figure 5. Relationship between innate immune recruitment and regression of 9L tumor xenografts. (A, B) Volumes of individual 9L
tumors that were untreated (UT; n = 3 tumors from three mice) or were given metronomic CPA at 140 mg/kg (n = 12 tumors). Four
tumors that partially regressed or were growth static are shown in A, and eight fully or near-fully regressing tumors are shown in B.
(C) qPCR analysis of tumor expression levels of the indicated factors. Data shown are for untreated 9L tumors on treatment day 0
(a, n = 6) or treatment day 24 (b, n = 6) and on day 6 after either 8 or 10 cycles of CPA treatment for fully responsive tumors (as in
B; c, n= 8) and for the partially regressing tumors (as in A; d, n= 4). *, **, ***P< .05, .01, and .001, respectively, versus UT on day 0 (a).
&, &&, &&&P < .05, .01, and .001, respectively, for partially regressing tumors (d) versus more completely regressing tumors (c), analyzed
by one-way ANOVA (nonparametric) with Bonferroni multiple comparison correction. The partially regressing tumors (d) were also sig-
nificantly different from the fully regressing tumors (c) when evaluated using Fisher exact test: CD68 and CD74, P< .02; FasL, P< .005;
NKp46, NKG2D, Cxcl14 and Fas, P < .001; GzmB and Prf1, P < .0001. See also Figure W5.
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Figure 6. Analysis of tumors unresponsive to second round of metronomic CPA treatment. (A) Tumor growth curves for two individual
9L tumors treated with CPA at 105 mg/kg BW per i.p. injection for seven CPA cycles, which induced tumor growth delay (cf. Figure 4A),
followed by six additional metronomic CPA cycles at 170 mg/kg BW per i.p. injection, which induced tumor growth stasis but not major
regression. (B) Tumor growth curves for two individual 9L tumors treated with CPA at 170 mg/kg BW per i.p. injection for 13 CPA cycles,
which induced tumor regression (as in Figure 4A), followed by a break of 36 days. CPA treatment was reinitiated on day 108 and continued
for five additional cycles at 170 mg/kg BW per i.p. injection, which induced tumor growth stasis but not major regression. (C) 9L tumor
sublines derived from individual tumors T1, T2, T3, and T4 (as in A and B) were grown in SCID mice. The responsiveness of each tumor
subline to CPA treatment at 170 mg/kg BW per i.p. injection beginning on treatment day 0, when mean tumor volumes were 350 to
400 mm3, is shown. Tumor growth data are based on one randomly selected tumor from each of n = 4 to 5 mice per treatment group.
Tumor volumes shown aremean± SE values, normalized to 100% on day 0. 9L, growth curve for parental 9L tumors, shown as a reference.
(D) qPCR analysis of expression levels of host (m, mouse) NK cell effectors GzmB and perforin (Prf1), on day 6 after either five CPA treat-
ment cycles (T1, T3, and T4 tumors) or six CPA cycles (T2 tumors). Error bars, mean ± SD for n = 3 replicate assays of samples from
tumors collected from n = 4 to 5 mice per treatment group.
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at 105 mg/kg every 6 days (Figure 4A). Characterization of the in-
completely responsive 9L tumors revealed a level of innate immune
cell recruitment significantly lower than in the more completely regres-
sing tumors from the same study, as indicated by reduced levels of
several NK cell markers (NKp46, NKG2D, GzmB, Prf1; Figure 5C ,
tumor groups d vs c). More modest reductions in infiltrating macro-
phage (CD68) and dendritic cells (CD74), in the chemokine CXCL14,
and in Fas and FasL, were also seen in the incompletely responsive
tumors compared to the fully regressing tumors. An inverse relation-
ship between tumor volume and the expression level of these innate
immune-related markers was seen across the full set of 12 individual
tumors (Figure W5), further highlighting the relationship between
immune cell recruitment and tumor regression.
Next, we investigated whether tumor regression could be achieved
in the 105 mg/kg every 6-day CPA treatment group (Figure 4A) by
increasing the dose of CPA after seven CPA cycles. Figure 6A shows
that tumor growth stasis, and not tumor regression, was achieved
when CPA was administered at a higher dose, 170 mg/kg per 6 days,
for six additional cycles (days 36-72). In other experiments, several
tumors that showed strong and apparently complete regression follow-
ing CPA treatment at 170 mg/kg every 6 days began to regrow when
CPA treatment was discontinued for a period of 36 days (Figure 6B).
A second round of tumor regression was not achieved, however, when
metronomic CPA treatment was reinitiated at the same dose and
schedule (170 mg/kg every 6 days; Figure 6B, days 108-132). This
could reflect depletion of immune cell reservoirs (cf. Figure W2), or
alternatively, it may involve immunosuppression, or acquired tumor
cell resistance to CPA.
To investigate the possibility that acquired tumor cell resistance
is responsible for the observed tumor insensitivity to a second round
of metronomic CPA treatment, tumors were excised and tumor cell
lines were prepared from the four individual tumors shown in Figure 6,
A and B (tumors T1-T4). All four tumor cell lines derived from the
in vivo metronomic CPA-resistant tumors showed a sensitivity to
activated CPA (EC50 = 5.9-8.3 μM) only moderately lower than that
of parental 9L tumor cells [half maximal effective concentration
(EC50) = 3.7-4.1 μM] when assayed in a 4-day cell culture growth
inhibition assay using chemically activated CPA (4-hydroperoxy–
CPA). Thus, prolonged metronomic CPA treatment in vivo does
not induce strong intrinsic tumor cell resistance to activated CPA.
Next, we investigated the responsiveness of the four tumor sublines
to metronomic CPA-induced immune cell recruitment and tumor
regression after reimplantation in tumor-naïve mice. All four 9L sub-
lines yielded tumors that showed consistent regression following metro-
nomic CPA treatment in vivo (170 mg/kg per 6 days; Figure 6C ).
Moreover, in each case, a strong antitumor innate immune response
was observed, marked by strong increases in the cytotoxic NK cell
effectors GzmB and perforin (Figure 6D).
Discussion
Metronomic CPA delivered using an every 6-day schedule activates a
potent antitumor innate immune response that leads to major regres-
sion of established brain tumor xenografts [16]. Here, we show that
this immune response is not recapitulated when using a more fre-
quent schedule of metronomic CPA administration, in particular, a
daily oral regimen [5], that results in the same net drug exposure and
that has served as a model for many clinical trials of metronomic
chemotherapy [7,9]. While the antiangiogenic actions of metro-
nomic CPA, and other agents, may contribute to antitumor activity
in certain tumor models [1,3], no antiangiogenesis was observed
using either the intermittent or the daily metronomic schedules in-
vestigated in this study. As such, metronomic chemotherapy-induced
antiangiogenic effects are likely drug and tumor model dependent.
These findings support our conclusion that innate immune recruit-
ment, and not antiangiogenesis, is the major mechanism for the strik-
ing tumor regression that is induced by metronomic CPA when
given on a 6-day repeating schedule in these subcutaneous brain
tumors, as seen in both SCID mice and in fully immune-competent
mice [16].
The empirical observation that a 6-day metronomic CPA schedule
is optimal with regard to antitumor activity [1] could reflect the life-
span of host immune cells or inflammation initiators such as plate-
lets, which are first-line immune responders to tissue damage and
have a life-span of 5 to 10 days [30]. While other metronomic chemo-
therapy schedules, including daily low-dose regimens, show improved
antitumor activity in some models [7], our findings indicate that the
every 6-day metronomic schedule used here may be optimal with
respect to activation of innate immunity: sufficiently frequent to re-
peatedly induce the tumor cell cytotoxicity and inflammation needed
to activate cytokine/chemokine attractants that stimulate an innate
immune response and sufficiently well spaced in time so as to mini-
mize the killing of chemosensitive immune cells recruited to the
tumor. Thus, intermittent (every 6 days) delivery of CPA as a bolus
injection may help ensure that a sufficient level of active drug is pres-
ent within the tumor microenvironment to induce cellular damage
and stimulate the production of immune cell chemoattractants. Fur-
ther supporting a minimum dose and tumor damage threshold re-
quirement, mathematical modeling comparing both conventional
and metronomic administration of temozolomide showed how lower-
ing drug dosage could lead to a decrease in therapeutic effect [31].
The striking difference in efficacy between daily low-dose and
intermittent bolus-dose metronomic CPA (Figure 1A) is not due
to differences in the route of administration (p.o. vs s.c.) or a dose
dependence of liver P450 enzyme–catalyzed prodrug activation (CPA
4-hydroxylation) [32], insofar as these comparisons between metro-
nomic schedules were carried out at the same net level of drug expo-
sure, as indicated by daily plasma AUC values (Figure 1C ). The
AUC level of active circulating drug generated here using low-dose
(daily p.o.) metronomic CPA was comparable to that reported pre-
viously for the same metronomic schedule and route [6], where
significant tumor growth delay (albeit no tumor regression) was
achieved in an s.c. prostate cancer PC-3 xenograft model. It should
be noted, however, that the significant tumor growth delay activity
of daily metronomic CPA seen in those studies and in several other
tumor models [5,6] was achieved when CPA treatment was initiated
when the tumors were small (up to ∼100 mm3) and perhaps partic-
ularly sensitive to antiangiogenesis-induced growth delay. In contrast,
in the present study daily metronomic CPA treatment was initiated
when the tumors were well established (∼300 mm3) and already well
vascularized and perhaps no longer hypersensitive to metronomic
CPA-induced antiangiogenesis. The glioma models used here (9L)
and in our earlier work (9L, U251) [16] are not resistant to anti-
angiogenesis per se; indeed, they are highly sensitive to antiangio-
genesis induced by targeted inhibitors of vascular endothelial growth
factor receptor [16,33]. These findings indicate that daily metronomic
CPA is comparatively weak as an antiangiogenic agent, at least when
assayed using these highly vascular s.c. glioma models.
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The schedule dependence of metronomic chemotherapy-induced
immune cell activation is likely to vary and will need to be optimized
for each drug. In addition to metronomic timing, optimized drug
dosage was found to be crucial for eliciting effective antitumor im-
munity and tumor regression. Thus, the strong recruitment of innate
immune cells stimulated by metronomic CPA at 140 mg/kg per 6 days
was not sustained, and tumor regression was abolished, by as little as a
25% reduction in CPA dose, with clear differences in effects on tumor
cellularity and proliferative capacity seen at higher (140 mg/kg) com-
pared to lower (70 and 105 mg/kg) CPA doses. Increasing the CPA
dose by ∼20%, to 170 mg/kg per 6 days, eliminated the partial tumor
regression and weak innate immune cell recruitment seen in a subset of
the every 6-day treated tumors. These steep dose dependencies suggest
a need for a critical threshold of DNA damage or cellular stress to ini-
tiate antitumor immunity and tumor regression. The dose dependence
and kinetics of onset of cell damage that triggers antitumor immunity
is likely to vary between tumors, as indicated by our finding that 9L
gliosarcomas treated with CPA at 140 mg/kg per 6 days do not begin
to regress until the third treatment cycle (Figure 1A) [33,34], whereas
tumor regression begins shortly after the first CPA cycle in the U251
glioblastoma and GL261 glioma models [16].
9L tumors that did not regress at a CPA dose of 105 mg/kg per 6
days failed to regress when subsequently treated with CPA at a dose
(170 mg/kg per 6 days) that readily regressed CPA-naïve tumors.
Moreover, when tumors that regressed following every 6-day CPA
treatment were allowed to regrow, they did not regress on reinitia-
tion of the same treatment regimen. Tumor cells derived from these
“metronomic CPA-resistant” tumors (Figure 6) were, however, intrin-
sically sensitive to activated CPA when assayed in cell culture, and they
exhibited normal metronomic CPA-induced regression patterns when
reimplanted in tumor-naïve mice. The loss of tumor responsiveness
could reflect the emergence of an immunosuppressive tumor envi-
ronment, or may be due to an impaired host innate immune response
after many cycles of CPA treatment, consistent with the observed
depletion of splenic immune cell reservoirs (Figure W2). This loss of
responsiveness is not due to the recruitment of Tregs, which are absent
in SCID mice. Furthermore, even in C57BL/6 mice, where Tregs are
expressed, the Treg population was not increased after several cycles of
metronomic CPA treatment at 140 mg/kg per 6 days [16], consistent
with other reports that metronomic chemotherapy depletes and/or
inhibits Tregs [12–15]. Another possible cause for the apparent loss in
responsiveness in our SCID mice could be induction of Gr1+CD11b+
bone marrow or myeloid-derived suppressor cells, which can suppress
antitumor immunity. However, we have found that metronomic CPA
treatment (140 mg/kg per 6 days) decreases, rather than increases, Gr1
+CD11b+ cell numbers in both spleen and bone marrow and does not
significantly increase these cells in treated 9L tumors (our unpublished
experiments). Taken together, these findings suggest that depletion of
sensitive innate immune cell populations and/or development of an
immunosuppressive tumor microenvironment is the cause for loss of
efficacy following long-term metronomic CPA treatment. Further
studies will be required to ascertain whether a similar loss of respon-
siveness occurs in fully immune-competent animal models and in
immune-competent patients.
Several mechanisms may contribute to metronomic CPA-induced
innate immune cell recruitment leading to tumor regression. Apop-
tosis, which is induced by CPA [35], can be immunogenic [36].
Further, one or more families of NK cell ligand-receptor pairs [37]
may mediate NK cell recruitment. This could involve an increase
in expression of NKG2D ligands following cytotoxic damage [38],
as indicated by the increase in the NKG2D ligand MICB in U251
glioblastoma treated with metronomic CPA every 6 days [16]. Chemo-
therapeutic drugs could also activate antitumor immunity through
their effects on transcriptional regulators of immune response factors.
For example, 5-fluouracil increases thrombospondin-1, implicated in
tumor macrophage recruitment [39], by up-regulation of Egr1, an
activator of the thrombospondin-1 promoter [40]. CPA can also elicit
a macrophage-associated antitumor response by activating a DNA
damage response pathway leading to tumor-specific secretion of high
mobility group box 1 protein [41]. Metronomic CPA-induced per-
sistent DNA damage may activate the senescence-associated secretory
phenotype, with secretion of factors that stimulate antitumor innate
immunity [42]. Further, we observed metronomic CPA activation of
tumor cell–expressed CXCL10 and CXCL11, which may contribute
to immune cell infiltration. CXCL10 is activated by cytotoxic tumor
cell stress [23] and both CXCL10 and CXCL11 can promote chemo-
taxis of activated NK and T cells [24]. However, NK cell recruitment
did not occur when these factors were induced by the daily and 70 mg/
kg per 3-day metronomic CPA regimens (Figure 3A), indicating these
factors alone are not sufficient to activate the antitumor innate immune
response. Conceivably, the intrinsic capacity of CXCL10 and CXCL11
to induce NK cell recruitment [24] may be countered by the killing off
of the responding NK cells due to their frequent exposure to activated
CPA when using the daily and the every 3-day CPA schedule.
While daily low-dose metronomic chemotherapy regimens may be
convenient and are widely employed in the clinic [7,9], they may not
always be optimal with regard to therapeutic effectiveness. Our studies
here show that the intermittent (every 6 days) bolus-dose approach
to metronomic chemotherapy, originally introduced by the Folkman
Laboratory [1], is mechanistically distinct, insofar as it provides for
drug-free breaks, which spare drug-sensitive innate immune cells es-
sential for a robust antitumor immune response. Other intermittent
metronomic drug schedules that show significant antitumor activity
include intermittent treatment with paclitaxel and epothilone drugs
(every 6, 8, 9, 12, and 14 days), which fully regress mammary, neuro-
blastoma, and ovarian tumor xenografts grown in nude mice [43].
Furthermore, intermittent metronomic chemotherapy can be safely
administered for prolonged periods of time [13]. While preclinical
models show that daily low-dose metronomic chemotherapy is also well
tolerated, tumor growth delay or, in some cases, tumor stasis is a com-
mon outcome and major sustained tumor regression is rarely achieved,
in contrast to our findings with intermittent metronomic dosing
of CPA. For example, daily oral low-dose metronomic CPA induces
only modest tumor growth delay in breast 231/LM2-4 tumors grown
orthotopically in nude mice [44]. Daily low-dose CPA induces only
an ∼20-day growth delay of orthotopic 231-H2N mammary tumors
[45], while PC-3 prostate cancer xenografts initially regress partially,
then become static, and then begin to regrow about 25 days later
[5]. As the latter treatment was initiated when the PC-3 tumors were
relatively small, the partial regression observed could reflect an initial
antiangiogenic response. In that same study, daily CPA treatment
induced a very modest growth delay of MDA-MB-231 xenografts
grown orthotopically in SCID mice [5].
The present findings have major implications for the design of
metronomic chemotherapeutic regimens in the clinic, where there is a
need for biomarkers to assess and optimize dose and schedule for effec-
tive activation of immune responses. Many cancer chemotherapeutics
have the potential to stimulate immune responses, even in the absence
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of metronomic scheduling. Thus, CPA promotes increased bone
marrow generation of dendritic cell precursors capable of antigen pre-
sentation [46] and differentiation of T helper 17 cells in both rodents
and humans [47], vinblastine induces dendritic cell maturation [48],
and the therapeutic efficacy of doxorubicin depends on CD8 T-cell
activation and interferon-γ production [49]. Antitumor immune acti-
vation may thus be an important mechanism of action for many anti-
cancer agents, including other conventional chemotherapeutics that
show efficacy when administered in metronomic schedules [48,50],
and warrants further study for its potential to elicit strong innate anti-
tumor immune responses in the clinic. Given the increased clinical use
of daily metronomic schedules of CPA and other anticancer drugs,
our finding that daily metronomic dosing of CPA does not recapitulate
the major innate immune recruitment that can be achieved using an
intermittent metronomic schedule should be taken into consideration
when developing immune-activating metronomic drug schedules for
evaluation in the clinic.
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Table W1. Oligonucleotide Primer Sets Used for qPCR Analysis.
Gene qPCR Primers (5′ to 3′)
Chemokine CXCL10
(Cxcl10) (rat-specific)
Forward: 5′-GAATCTGAGGCCATCAAGAGCTTAT-3′
Reverse: 5′-TGTCCATCGGTCTCAGCACTGT-3′
Chemokine CXCL11
(Cxcl11) (rat-specific)
Forward: 5′-GCTATGATCATCTGGGCCACAA-3′
Reverse: 5′-GGGTAAATTACAGAAACTTCCTTGATTG-3′
Fas ligand (Fasl, Cd95l)
(mouse-specific)
Forward: 5′-CTGGCAGAACTCCGTGAGTTC-3′
Reverse: 5′-CCACACTCCTCGGCTCTTTTT-3′
Primers were designed to anneal at their 3′ end in a mouse (host)–specific manner, except as noted.
Species alignments between human, rat, and mouse sequences were used for each gene to determine
primer set specificity. The absence of cross-species amplification was verified by testing primer sets on
a panel of rat, mouse, and human RNA to ensure species specificity. Gene names are shown in
parentheses. Sequences for the following mouse-specific primer sets were reported previously [16].
Fas receptor (Fas), NKp46 (Ncr1), perforin (Prf1), GzmB, natural killer cell factor 1.1 (NK1.1,
Klrb1c), NK chemoattractant CXCL14 (Cxcl14), NK cell receptor NKG2D (Klrk1), macrophage
marker CD68 (Cd68), dendritic cell marker CD74 (Cd74), neutrophil marker Gr1 (Ly6g; previously
designated Gr1/Ly6g), and endothelial cell marker CD31 (Pecam1).
Figure W1. Immunostaining and hematoxylin staining of 9L tumors. (A) Immunostaining of macrophage marker CD68 (original magni-
fication, ×4.2), NK cell marker NK1.1 (×40), and NK cell effector Prf1 (×20) in untreated 9L tumors (UT), or 9L tumors treated with CPA
through drinking water (1× p.o.) or every 3 days (70 mg/kg per i.p. injection). Tumors were analyzed on treatment day 24, as in Figure 2A.
(B) Hematoxylin staining (showing cell density), PCNA staining (showing cell viability), and immunostaining of endothelial cell marker
CD31 (all at ×20 magnification) for the same tumor groups shown in A.
Figure W2. Expression of immune cell markers in spleens of 9L tumor-bearing SCID mice. Mice were untreated (UT) or were treated with
various metronomic CPA regimens: oral, 23.3 mg/kg BW daily (1× po); oral, 70 mg/kg BW daily (3× po); i.p., 70 mg/kg BW every 3 days
(70/3 days); or i.p., 140 mg/kg every 6 days (140/6 days). Spleens were removed and analyzed on treatment days 0, 12, 18, or 24, as
marked. qPCR primers were specific for host (m, mouse) genes, including neutrophil marker Gr1, as in Figures 1D, 3, B and C ,
4, B and D, and 5B. Error bars, mean ± SD for n = 3 replicate assays of pooled samples from spleens collected from n = 2 to 3 mice
per treatment group.
Figure W3. Expression of the indicated immune cell and chemokine markers in metronomic CPA-treated 9L tumors. Tumor RNA samples
were assayed on day 6 after either four or seven metronomic CPA cycles, corresponding to treatment days 24 and 42 in Figure 4A.
Error bars, mean ± SE for n = 2 to 4 mice per treatment group. *, **, ***P < .05, .01, and .001, respectively, versus UT (CPA dose of
0 mg/kg BW). ^, ^^P < .05 and .01, respectively, versus CPA dose of 105 mg/kg BW treatment on day 6 after seven cycles of CPA
treatment. Data were analyzed by one-way ANOVA with Bonferroni multiple comparison correction for one tumor randomly selected from
each mouse.
Figure W4. 9L tumor hematoxylin staining. The figure shows relative 9L tumor cell density and morphologic changes in response to 6-day
metronomic CPA treatment at doses of 70, 105, 140, or 170 mg/kg. Tumors excised on treatment day 24 (6 days after the fourth cycle of
CPA/6-day treatment). Images shown are representative of n= 10 to 40 photos taken for each of n= 2 to 3 tumors randomly selected from
n = 2 to 3 mice per treatment group.
Figure W5. Inverse relationship between tumor volume and
expression level of innate immune-related markers. Data are from
9L tumors treated with metronomic CPA at 140 mg/kg per 6 days
for 24 days. Data presented in Figure 5 are regraphed to highlight
the inverse relationship between tumor volume and relative level
of tumor expression of the indicated six mouse genes on day 6 after
either 8 or 10 cycles of CPA treatment. Each data point represents
one of the 12 individual tumors included in this study (Figure 5), as
shown at the bottom, where the eight fully regressing tumors (final
tumor volume < 100 mm3, as in Figure 5B) and the four partially
regressing tumors (final tumor volume > 100 mm3, as in Figure 5A)
are identified by tumor number. For mice D7 and D8, one tumor was
in the full regression group (tumors D7L and D8L, respectively) and
one tumor was not (tumors D7R and D8R, respectively).
